Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 468

1.

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Pyŏrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G.

Diabetes Care. 1997 Apr;20(4):614-20. Erratum in: Diabetes Care 1997 Jun;20(6):1048.

PMID:
9096989
2.

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

Miettinen TA, Pyörälä K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J.

Circulation. 1997 Dec 16;96(12):4211-8.

3.

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

Pyörälä K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J; Scandinavian Simvastatin Survival Study (4S).

Diabetes Care. 2004 Jul;27(7):1735-40.

PMID:
15220255
4.

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K.

Arch Intern Med. 1999 Dec 13-27;159(22):2661-7.

PMID:
10597756
5.
6.

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J.

Circulation. 2001 Dec 18;104(25):3046-51.

7.

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyörälä K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ.

Circulation. 1998 Apr 21;97(15):1453-60.

8.

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.

Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, Olsson AG, Pyörälä K, Wedel H.

Am J Cardiol. 2000 Aug 1;86(3):257-62.

PMID:
10922429
10.

Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, Fatemian M, Kearney E, Lyon V, Mindell J, et al.

Eur Heart J. 1994 Feb;15(2):255-69.

PMID:
8005129
11.

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators.

Circulation. 2002 Mar 12;105(10):1162-9.

12.

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.

Hoogwerf BJ, Waness A, Cressman M, Canner J, Campeau L, Domanski M, Geller N, Herd A, Hickey A, Hunninghake DB, Knatterud GL, White C.

Diabetes. 1999 Jun;48(6):1289-94.

PMID:
10342818
14.

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Faergeman O, Thorgeirsson G, Jönsson B, Schwartz JS.

Circulation. 1996 May 15;93(10):1796-802. Erratum in: Circulation 1996 Aug 15;94(4):849.

15.

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.

Pedersen TR, Berg K, Cook TJ, Faergeman O, Haghfelt T, Kjekshus J, Miettinen T, Musliner TA, Olsson AG, Pyörälä K, Thorgeirsson G, Tobert JA, Wedel H, Wilhelmsen L.

Arch Intern Med. 1996 Oct 14;156(18):2085-92.

PMID:
8862101
16.

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

Diabetes Care. 2006 Jun;29(6):1220-6.

PMID:
16731999
17.

[The Scandinavian Simvastatin Survival Study: the clinical consequences].

Larsen ML.

Rev Esp Cardiol. 1995;48 Suppl 5:39-42. Spanish.

PMID:
7494939
18.

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.

JAMA. 1998 May 27;279(20):1615-22.

PMID:
9613910
19.

Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial.

Horiuchi H, Kita T, Mabuchi H, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, Saito Y, Sasaki J, Shimamoto K, Itakura H; J-LIT Study Group.

J Am Geriatr Soc. 2004 Dec;52(12):1981-7.

PMID:
15571531
20.

Statin trials and goals of cholesterol-lowering therapy after AMI.

Pedersen TR.

Am Heart J. 1999 Aug;138(2 Pt 2):S177-82. Review.

PMID:
10426879

Supplemental Content

Support Center